Topics:

New Retinoid Shows Promise as a Nontoxic Chemopreventive Agent

New Retinoid Shows Promise as a Nontoxic Chemopreventive Agent

SAN DIEGO--A retinoid with specificity for the RXR receptor has shown potential as a virtually nontoxic chemo-preventive agent for breast cancer.

The RXR ligand LGD1069 inhibited tumor formation in laboratory animals to the same degree as did tamoxifen (Nolvadex). The tumor inhibition occurred with no apparent signs of toxicity. These initial results have provided the basis for ongoing phase II/III trials of the synthetic retinoid, Dr. Marco M. Gottardis said at a general session of the San Antonio Breast Cancer Symposium.

The findings come from evaluations of animals that underwent NMU tumor induction, a model for hormone-dependent breast cancer. A week after exposure to NMU, the animals were given either LGD1069 (Targretin), at a dose of 30 or 100 mg/kg/day, or tamoxifen at a dose of 50 or 150 mg/kg/day. Control animals received no chemoprevention.

After 12 weeks, the control animals had a 100% incidence of mammary carcinoma, averaging three tumors per animal. The lower dose of tamoxifen resulted in a small reduction in tumor incidence, compared with controls, while the higher dose was associated with a 20% tumor incidence.

Both doses of LGD1069 matched or exceeded the chemopreventive effects of high-dose tamoxifen. Animals treated with high-dose tamoxifen or LGD1069 averaged fewer than 0.5 tumors, said Dr. Gottardis, a senior research scientist at Ligand Pharmaceuticals in San Diego.

Of note, the animals treated with LGD1069 had no mucocutaneous, skeletal, or dermatologic toxicity, which has often proved dose limiting with other retinoids. The animals also did not have weight loss, whereas tamoxifen-treated animals had significant weight loss.

No Effect on Hormonal Milieu

LGD1069 had no effect on the animals' hormonal milieu. Compared with controls, animals treated with the retinoid had no changes in levels of estradiol, progesterone, or prolactin.

Interestingly, Dr. Gottardis said, LGD1069 appeared to have reduced uterine proliferation (wet weight), compared with control animals. Agents that have antiestrogenic effects, such as tamoxifen, have been shown to increase uterine wet weight. "This difference is an interesting finding and might point to some mechanisms about how inhibition of tumor growth occurs with LGD1069," he said.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.